

Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis

HU WANG^{1*}, LI WANG^{1*}, YUJIA CHENG^{1*}, ZHIQING XIA¹, YIFENG LIAO¹ and JIANG CAO²

¹Department of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu 221004; ²Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China

Received December 14, 2017; Accepted May 10, 2018

DOI: 10.3892/br.2018.1100

Abstract. In the present meta-analysis, the efficacy and safety of orlistat in the treatment of non-alcoholic fatty liver (NAFLD) and non-alcoholic steatohepatitis (NASH) were evaluated. PubMed, Embase, the Cochrane Library, Web of Science, and Wan Fang data were searched for controlled trials of orlistat in patients with NAFLD or NASH, published before August 2017. Three randomized controlled trials and four single-arm trials were included. The involved participants with NAFLD or NASH (330 patients) were analyzed for clinical outcomes including alteration in hepatic histological variables and biomarkers of liver function. Improvements were observed in levels of alanine aminotransferase [standard mean difference (SMD)=-1.41; P=0.01], aspartate aminotransferase (SMD=-2.06; P=0.0005), γ -glutamyl transpeptidase (SMD=-1.91; P=0.05), glucose [mean difference (MD)=-0.51; P=0.01], triglycerides (MD=-0.93; P=0.01), homeostasis model assessment of insulin resistance index (MD=-1.05; P=0.04) and body mass index (MD=-1.97; P=0.02), but not in liver fibrosis score (SMD=-0.14; P=0.71). On sub-analyses of the different patient groups, no significant differences were observed in patients with NASH. Taken together, these findings demonstrate that orlistat could serve as a therapeutic drug to improve biochemical indicators of liver damage, but not as

first-choice drug for the management of NAFLD or NASH; thus suggesting a novel palliative drug only for the treatment of NAFLD.

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease characterized by hepatic fat accumulation in patients with little to no history of alcohol consumption (1). Up to 30% of the worldwide population is affected by NAFLD, among which populations in developed countries are particularly affected, including those in the United States (2,3). The occurrence and development of NAFLD are associated with metabolic syndrome, which comprises a group of disorders including obesity, increased plasma triglycerides (TGs) and reduced insulin sensitivity (4). More specifically, Li *et al* (5) reported that obesity may be an independent risk factor for NAFLD. NAFLD is considered a public health concern due to its potential to progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and even hepatocellular carcinoma (6,7). The primary therapy for NAFLD is lifestyle management to prevent obesity; however, long-term changes in eating habits and weight loss are difficult to achieve and maintain (8). Due to the lack of effective therapy options and consequences of disease progression, the development of novel pharmacological treatments for NAFLD should be actively pursued.

Orlistat is among the few types of over-the-counter diet pill available worldwide, and is a potent and long-lasting gastrointestinal lipase inhibitor that directly blocks intestinal absorption of dietary fat, and thus promotes weight loss (9,10). In clinical trials, patients treated with orlistat exhibited lower fasting glucose, fasting insulin, TGs, insulin resistance as assessed via the homeostasis model assessment of insulin resistance (HOMA-IR) and body mass index (BMI), along with greater weight loss compared with those treated with placebo (11-13). Furthermore, orlistat was demonstrated to reduce transaminase levels (14), commonly used as biomarkers to assess liver damage (14,15). As an inhibitor of gastroenteric lipase, the long-term application of orlistat is considered to have no toxic side effects (16); additionally, any adverse effects in the contexts of cardiovascular outcome and carcinogenesis are as yet unreported.

For these reasons, orlistat is expected to be an effective drug for the management of NAFLD; however, its efficacy remains controversial. Zelber-Sagi *et al* (17) identified that, compared

Correspondence to: Dr Jiang Cao, Department of Hematology, Affiliated Hospital of Xuzhou Medical University, 99 Huaihai West Road, Quanshan, Xuzhou, Jiangsu 221002, P.R. China
E-mail: hyfsh864@163.com

*Contributed equally

Abbreviations: NAFLD, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ -glutamyl transpeptidase; TG, triglyceride; HOMA-IR, homeostasis model assessment of insulin resistance; BMI, body mass index; RCT, randomized controlled trial; MD, mean difference; SMD, standard mean difference; 95% CI, 95% confidence interval

Key words: meta-analysis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, orlistat

with placebo, orlistat did not cause a significant reduction in body weight in patients with NAFLD. Thus, the purpose of the present systematic review and meta-analysis was to evaluate the efficacy and safety of orlistat in patients with NAFLD or NASH.

Materials and methods

Protocol. The meta-analysis was conducted by two investigators independently. Any differences in opinion were resolved by consensual agreement. The methods used adhered to the criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (18).

Literature search strategy. In August 2017, a computer-assisted search was performed of PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), Embase (<https://www.embase.com/#search>), Cochrane Library (<https://onlinelibrary-wiley-com.webproxy.potsdam.edu/cochranelibrary/search>), Web of Science (<http://isiknowledge.com>) and Wan Fang data (<http://www.wanfangdata.com.cn/index.html>) using the following combinations of terms: 'THLP' or 'tetrahydrolipastatin' or 'Xenical' or 'Roche brand of orlistat' or 'Hoffmann-La Roche brand of orlistat' or 'Alli' or 'GlaxoSmithKline brand of orlistat' and 'non-alcoholic fatty liver disease' or 'NAFLD' or 'nonalcoholic fatty liver disease' or 'fatty liver, nonalcoholic' or 'fatty livers, nonalcoholic' or 'liver, nonalcoholic fatty' or 'livers, nonalcoholic fatty' or 'nonalcoholic fatty liver' or 'nonalcoholic fatty livers' or 'nonalcoholic steatohepatitis' or 'nonalcoholic steatohepatides' or 'steatohepatides, nonalcoholic' or 'steatohepatitis, nonalcoholic'.

Inclusion and exclusion criteria. Database search results were screened using the following inclusion criteria: i) NAFLD or NASH diagnosed using results of liver biopsy or imaging; ii) orlistat prescribed to patients with NAFLD or NASH; iii) if present, controls were placebo, energy-controlled diet and/or vitamin E; and iv) the study classified as a randomized controlled trial (RCT) or an observational study. Exclusion criteria were: i) The use of animal or cell models; ii) orlistat prescribed in combination with other therapeutic drugs; iii) the study classified as a review or case report; and iv) treatment of sub-cohort groups with orlistat. No language restrictions were set.

Data extraction and quality assessment. The following data were extracted from the included studies: The first author, year of publication, sample size, length of follow-up, patient characteristics (country, sex ratio, mean age and obesity status), intervention (dose, duration and diet), control (placebo or other), liver histological variables and biomarkers for liver function [alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ -glutamyl transpeptidase (GGT), TGs, glucose and HOMA-IR]. Extracted data were verified by an independent investigator and any disagreements were resolved through discussion with a second investigator until a consensus was reached. The Cochrane Risk of Bias tool (19) and the Newcastle-Ottawa Quality Assessment Scale (20) were used to evaluate RCTs and observational studies, respectively. Safety was assessed based on reported treatment-related adverse events.

Statistical analysis. RevMan software (version 5.3; Cochrane, London, UK) was used for statistical analysis. Post-treatment




Figure 1. Flowchart of the literature search and study selection process.

and baseline values were extracted as means \pm standard deviations. For combined analyses, the mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI) to pool the extracted variables. The heterogeneity between studies was determined using the I^2 statistic; I^2 values of 25, 50 and 75% represented low, moderate and high heterogeneity, respectively (21). In cases with $I^2 < 50\%$, a fixed-effects model was used, whereas a random-effects model was used if $I^2 > 50\%$. $P < 0.05$ was considered to indicate statistical significance.

Results

Literature search. The database searches yielded 75 studies, of which 14 were excluded due to duplication. Following screening of titles and abstracts for eligibility, 43 additional studies were excluded. Of the remaining 18 studies, 11 were excluded following assessment of the full-text: Two conference abstracts, two duplicate protocols, one review, one case report, one study with sub-cohort treatment with orlistat and four studies with no outcomes of interest. Ultimately, seven studies were analyzed (11-13,17,22-24) (Fig. 1).

Trial characteristics. Trial characteristics of the seven included studies are summarized in Table I. Briefly, the trials were published between 2004 and 2017 and included 330 participants. The mean age of participants ranged from 36.5 to 58.5 years, and in all but one trial, the obesity rate was 100%. The duration of orlistat intervention ranged from 16 to 36 weeks, and in all studies, the dose administered was 120 mg three times a day. The study by Fan *et al* (22) analyzed two treatment durations (12 and 24 weeks); due to more comprehensive reporting on the 24-week data, the 24-week group was selected for inclusion in the meta-analysis.

Quality assessment. Quality assessment of the three included RCTs (11,17,23) was performed using the Cochrane Risk of Bias tool (Fig. 2). Overall, all three studies had a low risk of

Table I. Characteristics of the included studies.

Author (refs.)	Year of publication	Country	n	Number of women, n (%)	Dropout, n (%)	Mean age, years	Intervention dose, mg tid	Comparators	Duration	Obesity, %	Diagnosis	Study type
Chen <i>et al</i> (12)	2006	China	30	5 (16.7)	0 (0)	37.8	120	No control	24 weeks	100.0	NAFLD	Single-arm trial
Fan <i>et al</i> (22)	2004	China	60	23 (38.3)	2 (3.3)	36.5	120	No control	24 weeks	100.0	NAFLD	Single-arm trial
Harrison <i>et al</i> (13)	2004	USA	10	6 (60.0)	0 (0)	54.4	120	No control	6 months	100.0	NASH	Single-arm trial
Harrison <i>et al</i> (23)	2009	USA	50	0 (0)	9 (18.0)	47	120	Vitamin E (800 IU) + 1,400-calorie diet	36 weeks	100.0	NASH	RCT
Hussein <i>et al</i> (24)	2007	Israel	16	10 (62.5)	2 (12.5)	42	120	No control	6 months	100.0	NASH	Single-arm trial
Ali Khan <i>et al</i> (11)	2017	India	112	35 (31.3)	14 (12.5)	58.5	120	Diet	16 weeks	100.0	NAFLD	RCT
Zelber-Sagi <i>et al</i> (17)	2006	Israel	52	25 (48.1)	8 (15.4)	47.7	120	Placebo	6 months	71.2	NAFLD	RCT

NAFLD, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; RCT, randomized controlled trial; tid, three times a day.

	Zelber-Sagi 2006	Khan 2017	Harrison 2009	
	+	?	+	Random sequence generation (selection bias)
	+	?	+	Allocation concealment (selection bias)
	+	-	+	Blinding of participants and personnel (performance bias)
	+	-	+	Blinding of outcome assessment (detection bias)
	-	-	?	Incomplete outcome data (attrition bias)
	+	+	+	Selective reporting (reporting bias)
	+	+	+	Other bias

Figure 2. Summary of risk of bias assessments for the three randomized controlled trials included in the meta-analysis.

bias in selective reporting and other areas. Additionally, two of the studies (17,23) had low risk of bias in random sequence generation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessment. The number and cause of dropouts were identified for each study.

Quantitative data synthesis

ALT. ALT levels were reported in all included studies. Although between-study heterogeneity was high ($I^2=95\%$), orlistat post-treatment significantly reduced ALT levels compared to baseline [SMD=-1.41; 95% confidence interval (95% CI)=-2.52 to -0.30; $P=0.01$]. Specific subgroup analysis indicated no significant improvement in ALT levels in patients with NAFLD (SMD=-1.17; 95% CI=-2.55 to 0.21; $I^2=96\%$; $P=0.1$) or NASH (SMD=-1.80; 95% CI=-4.46 to 0.86; $I^2=96\%$; $P=0.18$; Fig. 3A).

AST. AST levels were reported in six of the seven studies analyzed. Compared to baseline, orlistat treatment significantly reduced AST levels (SMD=-2.06; 95% CI=-3.23 to -0.89; $P=0.0005$); however, between-study heterogeneity was high ($I^2=93\%$). In the subgroup analysis, significant difference in AST was identified in patients with NAFLD (SMD=-2.42; 95% CI=-3.95 to -0.90; $I^2=93\%$; $P=0.002$), but not in those with NASH (SMD=-1.75; 95% CI=-4.17 to 0.67; $I^2=95\%$; $P=0.16$; Fig. 3B).

GGT. The effect of orlistat on GGT levels reported in three studies was analyzed. Orlistat treatment significantly reduced GGT levels compared to baseline (SMD=-1.91; 95% CI=-3.79 to -0.03; $P=0.05$); however, between-study heterogeneity was high ($I^2=96\%$; Fig. 3C).

Liver histology. In four studies included in the meta-analysis, liver biopsies were administrated on admission and iterated following the treatment with orlistat. Fibrosis was scored on a scale from 0 to 4 (25). No significant differences between post-treatment and baseline scores were observed (SMD=-0.14; 95% CI=-0.88 to 0.60; $P=0.71$) in patients treated with orlistat. Between-study heterogeneity was high ($I^2=77\%$; Fig. 3D).

Glucose. Orlistat treatment caused significant reduction in fasting plasma glucose levels compared to baseline in patients




Figure 3. Forest plots illustrating improvement in biochemical and liver histological variables following treatment with orlistat. (A) Alanine aminotransferase; (B) aspartate aminotransferase; (C) γ -glutamyl transpeptidase; and (D) fibrosis score. NAFLD, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; SD, standard deviation; 95% CI, 95% confidence interval; IV, independent variable.

with NAFLD and NASH (SMD=-0.51; 95% CI=-0.91 to -0.11; $P=0.01$). Between-study heterogeneity was moderate ($I^2=31\%$; Fig. 4A).

Plasma triglycerides. The effect of orlistat on TG levels in five studies was analyzed. Overall, despite high heterogeneity ($I^2=88\%$), TG levels were significantly reduced following orlistat treatment compared to baseline (MD=-0.93;

95% CI=-1.67 to -0.19; $P=0.01$). Subgroup analysis determined a significant difference in patients with NAFLD (SMD=-0.45; 95% CI=-0.74 to -0.16; $I^2=28\%$; $P=0.002$), but not in patients with NASH (SMD=-2.11; 95% CI=-6.00 to 1.79; $I^2=96\%$; $P=0.29$; Fig. 4B).

HOMA-IR. HOMA-IR levels were reported in four studies. Compared to baseline, orlistat treatment caused a modest, but




Figure 4. Forest plots illustrating improvement in biochemical and anthropometric variables. (A) Fasting glucose; (B) triglycerides; (C) homeostasis model assessment of insulin resistance; and (D) body mass index. NAFLD, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; SD, standard deviation; 95% CI, 95% confidence interval; IV, independent variable.

significant, reduction in insulin resistance ($MD = -1.05$; 95% $CI = -2.05$ to -0.05 ; $I^2 = 85\%$, $P = 0.04$; Fig. 4C).

BMI. Data from five studies were used to evaluate BMI (Fig. 4D). Compared to baseline, orlistat treatment significantly reduced BMI ($MD = -1.97$; 95% $CI = -3.60$ to -0.33 ; $P = 0.02$), although between-study heterogeneity was high ($I^2 = 89\%$). Subgroup analysis identified a significant difference in patients with NAFLD ($MD = -2.31$; 95% $CI = -4.10$ to -0.51 ;

$I^2 = 94\%$; $P = 0.01$) but not in patients with NASH ($MD = -0.69$; 95% $CI = -6.07$ to 4.69 ; $I^2 = 67\%$; $P = 0.80$).

Adverse events. Of the seven studies included in the meta-analysis, four reported adverse events (11,17,22,24). Zelber-Sagi *et al* (17) reported that 2 patients withdrew from the study due to gastrointestinal side effects. Fan *et al* (22) reported that 2 patients withdrew from the study due to fecal urgency and fecal incontinence following 8 weeks of treatment.

Mild gastrointestinal discomfort symptoms, including nausea, abdominal cramps, fecal urgency, fecal incontinence and increased defecation were also reported (11,12,17,22,24). No serious treatment-related adverse effects on cardiovascular outcome or carcinogenesis were reported in any of the included studies.

Discussion

The present study to the best of our knowledge is the first systematic review and meta-analysis investigating the efficacy and safety of orlistat intervention in patients with NAFLD or NASH. Following a review of the literature, seven trials were identified that satisfied the inclusion criteria. Although the results of the current analysis are limited by the relatively small number of studies included, the data suggest improvements in biochemical, metabolic and anthropometric indicators of liver disease and in overall safety by orlistat treatment in patients with NAFLD or NASH.

In the studies analyzed, orlistat improved biochemical markers of liver disease. Orlistat treatment reduced the levels of ALT, AST and GGT compared to baseline in patients with NAFLD; however, the subgroup analysis did not reveal significant differences in patients with NASH. Aminotransferases are sensitive indicators of liver damage and cellular integrity and are mainly located in hepatocytes (14,15,26). When hepatocytes are damaged, for example during liver disease, blood aminotransferase levels increase (15). It is considered that orlistat may reduce damage to hepatocytes by decreasing fat accumulation in the liver, and thereby decrease aminotransferase levels (23).

However, the effect of orlistat on liver histological variables remains unclear. Overall assessment of the four studies noting liver fibrosis score revealed no significant changes in the scores following treatment with orlistat compared to baseline. These results are consistent with those of Tilg and Moschen (27) who demonstrated that orlistat failed to improve the histopathology of NAFLD. Therefore, orlistat should not be considered as a medication for alleviating fibrosis in patients with NAFLD or NASH.

As an anti-obesity drug, orlistat has been demonstrated to reduce postprandial lipid levels following high-fat meals. A study by Gabriel *et al* (28) identified that administration of orlistat suppressed the postprandial rise of TG levels in healthy adult volunteers following consumption of meals with 50% fat. Nakou *et al* (29) observed a greater decrease in TG levels with ezetimibe plus orlistat therapy compared with monotherapy with ezetimibe alone. In the current meta-analysis, TG levels were markedly improved following orlistat treatment compared to baseline, suggesting that orlistat may alleviate lipid accumulation, although statistical significance was not achieved in patients with NASH.

The present results also indicated that orlistat treatment reduced plasma glucose levels compared to baseline in patients with NAFLD and NASH. Kujawska-Łuczak *et al* (30) observed similar results while examining the effect of orlistat on glucose/insulin homeostasis in obese premenopausal women. Orlistat has been further indicated to improve glycemic control and insulin resistance, as well as reduce body weight gain and BMI, in patients with obesity and type 2 diabetes (31,32). Based on

these data, the effect of orlistat on insulin resistance and BMI in patients with NAFLD was analyzed. HOMA-IR was used to evaluate insulin resistance and BMI substituted for incomplete data on body weight. As expected, improvement in BMI was associated with improved insulin resistance, and HOMA-IR scores and BMI were significantly lower following orlistat treatment compared to baseline.

Previous results have indicated that hepatic steatosis and inflammation may be improved by weight loss or reduction of BMI (33). However, Harrison *et al* (23) reported that no significant differences in hepatic steatosis and inflammation were found between orlistat/diet/vitamin E and diet/vitamin E groups. The limited information collected on this aspect in our included studies hampered analysis of hepatic steatosis, necroinflammation and ballooning. Of the included studies, only two reported on steatosis and inflammation (23,24), and one on ballooning (23). Thus, further studies are required to investigate whether orlistat may improve liver histology.

Several limitations of the current analysis should be noted. First, a relatively small number of studies and sample sizes were included in the meta-analysis. Second, a high heterogeneity was observed, probably in part due to the small sample sizes, inconsistent duration of treatment, and lack of control groups, which prevented the evaluation of clinically significant conclusions. Third, only three studies investigated liver histological variables in patients with NAFLD and NASH.

In conclusion, the present systematic review and meta-analysis assessed the effect of the anti-obesity drug orlistat on various disease biomarkers in patients with NAFLD and NASH. The results suggest that, although orlistat does not consistently reverse liver fibrosis, it appears to improve other biochemical, metabolic and anthropometric indicators and to a certain extent, may contribute to prognosis. However, due to the limited sample size and high heterogeneity, these findings did not prove statistically significant in all subgroup analyses. Nonetheless, the data support the use of orlistat as a therapeutic strategy to improve biochemical indicators of liver damage, but not as a drug of choice for the management of NAFLD or NASH. Larger sample sizes and additional liver histological parameters (including hepatic steatosis, ballooning, necroinflammation and fibrosis) should be assessed over a longer follow-up period in future studies.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81470303), the Top-notch Academic Programs Project of Jiangsu Higher Education Institutions (grant no. PPZY2015B161) and the Jiangsu Province Students Innovation and Entrepreneurship Training Program (grant no. 201710313022Z).

Authors' contributions

HW and YC conducted the meta-analysis including design and drafting of the manuscript. LW and ZX verified the data

extracted following the literature search. HW, YL and JC were responsible for proofreading and revising the review critically for intellectual content. All authors read and approved the final manuscript.

Availability of data and materials

All data generated and/or analyzed during this study are included in this published article.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Bellentani S, Scaglioni F, Marino M and Bedogni G: Epidemiology of non-alcoholic fatty liver disease. *Dig Dis* 28: 155-161, 2010.
- Lazo M and Clark JM: The epidemiology of nonalcoholic fatty liver disease: A global perspective. *Semin Liver Dis* 28: 339-350, 2008.
- Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH and Li YM: Prevalence of nonalcoholic fatty liver disease and economy. *Dig Dis Sci* 60: 3194-3202, 2015.
- Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H and Svegliati-Baroni G: From the metabolic syndrome to NAFLD or vice versa? *Dig Liver Dis* 42: 320-330, 2010.
- Li L, Liu DW, Yan HY, Wang ZY, Zhao SH and Wang B: Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies. *Obes Rev* 17: 510-519, 2016.
- Zhao ZH, Liu XL and Fan JG: Research on the natural history of non-alcoholic fatty liver disease should be taken seriously. *Zhonghua Gan Zang Bing Za Zhi* 25: 81-84, 2017 (In Chinese).
- Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwithaya P, Topping JH, Bugianesi E, *et al*: The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. *Hepatology* 54: 1208-1216, 2011.
- Duvnjak M, Tomasic V, Gomercic M, Smircic Duvnjak L, Barsic N and Lerotic I: Therapy of nonalcoholic fatty liver disease: Current status. *J Physiol Pharmacol* 60 (Suppl 7): 57-66, 2009.
- Narayanaswami V and Dwoskin LP: Obesity: Current and potential pharmacotherapeutics and targets. *Pharmacol Ther* 170: 116-147, 2017.
- Kushner RF: Medical management of obesity. *Semin Gastrointest Dis* 13: 123-132, 2002.
- Ali Khan R, Kapur P, Jain A, Farah F and Bhandari U: Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. *Ther Clin Risk Manag* 13: 139-149, 2017.
- Chen Z, Liang B, Wang Y and Fan X: The analysis of the efficacy and risk factors in obesity with non-alcoholic fatty liver disease subjects treated with orlistat. *Chin J Clin Hepatol* 22: 123-124, 2006 (In Chinese).
- Harrison SA, Finck C, Helinski D, Torgerson S and Hayashi P: A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. *Aliment Pharmacol Ther* 20: 623-628, 2004.
- Fernández S and Córdoba M: Progesterone causes metabolic changes involving aminotransferases and creatine kinase in cryopreserved bovine spermatozoa. *Anim Reprod Sci* 164: 90-96, 2016.
- Bruinsma BG, Wu W, Ozer S, Farmer A, Markmann JF, Yeh H and Uygur K: Warm ischemic injury is reflected in the release of injury markers during cold preservation of the human liver. *PLoS One* 10: e0123421, 2015.
- Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP and Elisaf MS: Orlistat-associated adverse effects and drug interactions: A critical review. *Drug Saf* 31: 53-65, 2008.
- Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z and Oren R: A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 4: 639-644, 2006.
- Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int J Surg* 8: 336-341, 2010.
- Furlan AD, Pennick V, Bombardier C and van Tulder M; Editorial Board, Cochrane Back Review Group: 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. *Spine* 34: 1929-1941, 2009.
- Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 25: 603-605, 2010.
- Li Z, Xue J, Chen P, Chen L, Yan S and Liu L: Prevalence of non-alcoholic fatty liver disease in mainland of China: A meta-analysis of published studies. *J Gastroenterol Hepatol* 29: 42-51, 2014.
- Fan Z, Qiu D, Xie W, Hu H, Chen Y, Sun Z, Liu S and Zeng M: Clinical study of obesity associated non-alcoholic fatty liver disease. *Chin Hepatol* 9: 155-158, 2004 (In Chinese).
- Harrison SA, Fecht W, Brunt EM and Neuschwander-Tetri BA: Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. *Hepatology* 49: 80-86, 2009.
- Hussein O, Grosowski M, Schlesinger S, Szvalb S and Assy N: Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH). *Dig Dis Sci* 52: 2512-2519, 2007.
- Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, *et al*: The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 45: 846-854, 2007.
- Mahboub P, Ottens P, Seelen M, 't Hart N, Van Goor H, Ploeg R, Martins PN and Leuvenink H: Gradual rewarming with gradual increase in pressure during machine perfusion after cold static preservation reduces kidney ischemia reperfusion injury. *PLoS One* 11: e0152006, 2016.
- Tilg H and Moschen A: Weight loss: Cornerstone in the treatment of non-alcoholic fatty liver disease. *Minerva Gastroenterol Dietol* 56: 159-167, 2010.
- Gabriel FS, Samson CE, Abejuela ZR, Sicut-Gabriel PR, Sumpio JP, Zacarias MB and Mercado-Asis LB: Postprandial effect of orlistat on the peaking of lipid level after sequential high fat meals. *Int J Endocrinol Metab* 10: 458-463, 2012.
- Nakou ES, Filippatos TD, Agouridis AP, Kostara C, Bairaktari ET and Elisaf MS: The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. *Lipids* 45: 445-450, 2010.
- Kujawska-Łuczak M, Musialik K, Szulińska M, Swora-Cwynar E, Kargulewicz A, Grzymisławska M, Pupek-Musialik D and Bogdański P: The effect of orlistat versus metformin on body composition and insulin resistance in obese premenopausal women: 3-month randomized prospective open-label study. *Arch Med Sci* 13: 725-731, 2017.
- Scheen AJ and Van Gaal LF: Combating the dual burden: Therapeutic targeting of common pathways in obesity and type 2 diabetes. *Lancet Diabetes Endocrinol* 2: 911-922, 2014.
- Smith-Marsh D: Pharmacological strategies for preventing type 2 diabetes in patients with impaired glucose tolerance. *Drugs Today (Barc)* 49: 499-507, 2013.
- Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 142: 1592-1609, 2012.